Inovio Pharmaceuticals Conference Call Summary Company Overview - Inovio Pharmaceuticals is a clinical-stage biotech company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2][3] - The company has submitted a Biologics License Application (BLA) for its lead program, INO-3107, which targets Recurrent Respiratory Papillomatosis (RRP) caused by HPV types 6 and 11 [2][3] Regulatory Status - The BLA for INO-3107 has been accepted for review by the FDA under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026 [3] - Inovio has received Orphan Drug and Breakthrough Therapy designations for INO-3107 [3] - The company is preparing to address preliminary comments from the FDA regarding eligibility for the Accelerated Approval Program [3][27] Product Details - INO-3107 is a combination product that includes a DNA medicine and a delivery device [3] - The treatment aims to generate an antigen-specific T-cell response against HPV6 and HPV11, addressing the underlying cause of RRP rather than just managing symptoms through surgery [9][10] - Epidemiology suggests approximately 14,000 active RRP cases in the U.S., with an incidence rate of 1.8 per 100,000 annually [7] Clinical Data - Efficacy data shows that 72% of patients experienced a 50%-100% reduction in surgeries in the first year, improving to 86% in the second year [11] - Complete response rates were 28% in year one and 50% in year two, indicating a significant reduction in the need for surgeries [11] - The treatment was well tolerated, with common adverse events being transient injection site pain (30% of participants) and fatigue, but no discontinuations were reported [12] Competitive Landscape - Inovio believes it has a preferred product profile compared to existing treatments, particularly due to its improved safety profile and the ability to administer the treatment in a doctor's office without the need for surgeries [29][45] - The approved product requires scoping and surgeries, which adds logistical burdens and risks for patients [45][63] Manufacturing and Commercialization - INO-3107 is manufactured at FDA-approved contract manufacturers, with the drug substance produced by one manufacturer and the final product filled by another [51] - The company is preparing for commercial launch, including market research and establishing distribution channels [58][61] Future Pipeline - Following INO-3107, Inovio has other candidates in development, including INO-5401 and INO-3112, which are T-cell based therapies [13][14] - The company is also exploring next-generation therapeutics for protein replacement diseases [14] Regulatory Feedback - Inovio has received differing feedback from European regulators, who are looking for placebo-controlled data and data from two efficacy trials, contrasting with the FDA's approach [39][41] Investor Insights - Inovio emphasizes the potential of its T-cell technology and the exciting prospects of its dMAb and dProt programs, which are gaining interest from potential partners [64][66]

Company Overview - Inovio Pharmaceuticals is a clinical-stage biotech company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2] - The company has recently had its Biologics License Application (BLA) for its lead program, INO-3107, accepted for review by the FDA, marking a significant milestone [2] Product Pipeline - INO-3107 is a potential treatment for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11 [2] - The FDA accepted the BLA under the accelerated approval program and granted a standard review, indicating a positive regulatory outlook for the product [2]

Inovio Pharmaceuticals FY Conference Summary Company Overview - **Company**: Inovio Pharmaceuticals (NasdaqCM: INO) - **Focus**: Developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [4][5] - **Lead Candidate**: INO-3107, targeting recurrent respiratory papillomatosis (RRP) caused by HPV 6 and 11 [4][5] Regulatory Updates - **BLA Acceptance**: INO-3107's Biologics License Application (BLA) accepted for review by the FDA under the Accelerated Approval Program with a PDUFA target date of October 30, 2026 [5][19] - **Designations**: Received Orphan Drug designation and Breakthrough Therapy designation from the FDA and Orphan Drug designation in the EU [5] - **Regulatory Challenges**: Disappointment over not receiving priority review; FDA indicated inadequate information for Accelerated Approval eligibility [19][20] Market Opportunity - **RRP Prevalence**: Approximately 14,000 active cases in the U.S., with potential underestimation of market opportunity [12][39] - **Surgery Burden**: Patients may require hundreds of surgeries over a lifetime, leading to significant unmet needs [12][13] - **Competitor Pricing**: Competitor's treatment priced at approximately $115K per dose, indicating a lucrative market for RRP treatments [39] Product Profile and Efficacy - **Efficacy Data**: INO-3107 shows a 50%-100% reduction in surgeries after treatment, with 72% in year 1 improving to 86% in year 2; 28% of patients required no surgeries in year 1, increasing to 50% in year 2 [14][15] - **Safety Profile**: Well-tolerated with transient injection site reactions; no treatment discontinuations reported [15] - **Administration**: Office-based administration with no need for ultra-cold chain storage, making it easier for healthcare professionals [16] Clinical Pipeline - **Future Trials**: Plans to initiate Phase III trial for INO-3112 and Phase II trial for INO-5401 in glioblastoma; advancing DPROT platform candidates from preclinical to Phase I [17][41] - **dMAb Technology**: Exciting early-stage technology with potential to unlock further applications of DNA medicines [6][41] Immunogenicity and Redosing Strategy - **Comparison with Adenoviral Approaches**: INO-3107 avoids generating immune responses against viral vectors, allowing for multiple redosing without the risk of neutralizing antibodies [35][36][38] - **Redosing Plans**: Potential annual redosing strategy post-approval to maintain cytotoxic T-cell responses [38] Upcoming Milestones - **PDUFA Date**: Focus on the upcoming PDUFA date in October 2026; awaiting FDA meeting to discuss preliminary comments [17][43] - **Market Research**: Ongoing research to support launch strategy and address unmet needs in the RRP community [39][40] Conclusion - Inovio Pharmaceuticals is positioned to address significant unmet needs in the RRP market with its lead candidate INO-3107, supported by promising efficacy and safety data. The company is actively engaging with regulatory bodies to navigate the approval process while also advancing its broader clinical pipeline.

Core Viewpoint - INOVIO's Biologics License Application (BLA) for INO-3107 has been accepted by the FDA for review as a potential treatment for adults with recurrent respiratory papillomatosis (RRP), with a standard review classification assigned [1][2] Group 1: FDA Review Process - The FDA has set a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, for INO-3107, indicating when it intends to take action on the application [2] - INOVIO filed the BLA under the accelerated approval pathway, although the FDA has raised concerns about the adequacy of information submitted for this pathway [3] Group 2: Clinical Data and Efficacy - INO-3107 has shown potential therapeutic benefits in clinical trials, with 72% of patients experiencing a 50-to-100% reduction in surgeries after one year of treatment, increasing to 86% in the second year without additional dosing [6][4] - The BLA is supported by data from a Phase 1/2 trial involving adult patients with RRP who had undergone multiple surgeries prior to treatment, demonstrating long-term clinical benefits [4][6] Group 3: Disease Background and Market Need - RRP is a rare disease primarily caused by HPV-6 and HPV-11, leading to the development of benign papillomas in the respiratory tract, which can cause severe complications [5] - Current standard care involves surgical removal of papillomas, but they often regrow, highlighting the need for effective non-surgical treatment options [5] Group 4: INO-3107 and its Mechanism - INO-3107 is designed to elicit a T cell response against HPV-6 and HPV-11, potentially preventing or slowing the growth of new papillomas [6][7] - The treatment has shown a strong immune response and was well tolerated in clinical trials, with mostly low-grade adverse effects reported [6][7] Group 5: Regulatory Designations and Market Access - INO-3107 has received Orphan Drug and Breakthrough Therapy designations from the FDA, as well as Orphan Drug designation from the European Commission [8] - The CELLECTRA delivery device has been CE-marked in the EU, allowing for commercialization in regions recognizing this certification [8]

Core Insights - INOVIO has completed the rolling submission of its Biologics License Application (BLA) for its lead candidate INO-3107, aimed at treating Recurrent Respiratory Papillomatosis (RRP) in adults, under the FDA's accelerated approval program [2][3][6] - The company is preparing for a potential commercial launch of INO-3107 in mid-2026, which would mark its first commercial product and the first DNA medicine available in the United States [3][6] - Recent data from clinical trials indicate that INO-3107 significantly reduces the need for surgeries in patients, with 81% of patients experiencing a reduction in surgeries at Year 1 and 91% at Year 2 post-treatment [7][5] Operational Highlights - INOVIO is conducting a confirmatory trial for INO-3107, expected to enroll patients during the BLA review period at approximately 20 sites across the United States [4] - The company has published proof-of-concept data on its next-generation DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine, showcasing its potential as a long-acting alternative to traditional therapies [8][6] - INOVIO's DPROT program is set to present promising preclinical data at the World Federation of Hemophilia Global Forum, focusing on in vivo therapeutic protein production [9] Financial Performance - For Q3 2025, INOVIO reported a net loss of $45.5 million, an increase from a net loss of $25.2 million in Q3 2024, primarily due to a non-cash loss on fair value adjustment related to warrant liabilities [13][20] - Research and Development (R&D) expenses decreased to $13.3 million from $18.7 million year-over-year, while General and Administrative (G&A) expenses also saw a decline to $7.9 million from $8.6 million [13][20] - As of September 30, 2025, INOVIO had cash, cash equivalents, and short-term investments totaling $50.8 million, down from $94.1 million at the end of 2024, with an estimated operational net cash burn of approximately $22 million for Q4 2025 [12][13]

Core Viewpoint - INOVIO is on track to complete the Biologics License Application (BLA) for INO-3107 by the end of 2025, with the FDA agreeing to its rolling submission timeline for the treatment of Recurrent Respiratory Papillomatosis (RRP) [1][2] Group 1: Company Overview - INOVIO is a biotechnology company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases [7] - The company utilizes a proprietary DNA medicines platform that includes DNA plasmids and the CELLECTRA delivery device, which optimally delivers DNA medicines without the need for chemical adjuvants [6] Group 2: Product Information - INO-3107 is an investigational DNA medicine targeting HPV-6 and HPV-11, designed to elicit a T cell response to combat these infections [4] - In a Phase 1/2 trial, 72% of patients experienced a 50-to-100% reduction in surgeries after one year of treatment with INO-3107, increasing to 86% after two years [4] Group 3: Regulatory Designations - INO-3107 has received Orphan Drug and Breakthrough Therapy designations from the FDA, allowing for accelerated approval based on Phase 1/2 trial data [5] - The European Commission has also granted Orphan Drug designation to INO-3107, and the UK has awarded it the Innovation Passport [5] Group 4: Market Context - RRP is a rare disease primarily caused by HPV-6 and HPV-11, characterized by wart-like growths in the respiratory tract, which can lead to severe complications [3] - The estimated prevalence of RRP in the U.S. is about 14,000 active cases, with approximately 1.8 new cases per 100,000 adults each year [3]

Core Insights - INOVIO announced its financial results for Q2 2025 and provided updates on its product development, particularly focusing on INO-3107 for Recurrent Respiratory Papillomatosis (RRP) [1][9] Financial Performance - R&D expenses decreased to $14.5 million in Q2 2025 from $23.1 million in Q2 2024, primarily due to lower drug manufacturing and clinical study expenses [16] - G&A expenses also decreased to $8.6 million in Q2 2025 from $10.2 million in Q2 2024, attributed to reduced stock-based compensation and lower outside services [16] - Total operating expenses fell to $23.1 million in Q2 2025 from $33.3 million in Q2 2024 [16] - Net loss for Q2 2025 was $23.5 million, or $0.61 per share, down from a net loss of $32.2 million, or $1.19 per share, in Q2 2024 [16][19] Product Development Updates - INOVIO completed device DV testing for CELLECTRA 5PSP and requested FDA rolling submission for BLA of INO-3107, aiming for acceptance by year-end 2025 [2][3] - INOVIO is preparing for a confirmatory trial with 100 patients across 20 sites in the U.S. [3] - A retrospective study showed significant clinical benefits of INO-3107, with surgery reduction rates improving from 72% in Year 1 to 86% in Year 2 [4][6] Upcoming Events and Presentations - INOVIO plans to present data on INO-3107 and other DNA medicine candidates at several upcoming conferences, including the American Academy of Otolaryngology and the World Vaccine Congress Europe [7] Cash Position and Guidance - As of June 30, 2025, INOVIO had cash, cash equivalents, and short-term investments totaling $47.5 million, down from $94.1 million at the end of 2024 [16] - The company estimates its cash resources will support operations into Q2 2026, with a projected net cash burn of approximately $22 million for Q3 2025 [11]

Core Insights - INOVIO announced positive long-term clinical data for INO-3107, showing a significant reduction in surgeries for patients with recurrent respiratory papillomatosis (RRP) [1][2] - The retrospective study published in The Laryngoscope indicates that the majority of patients maintained or improved their surgical response two years post-treatment [2][5] Summary by Sections Clinical Data and Efficacy - A retrospective study involving 28 of the original 32 patients from a Phase 1/2 trial showed an Overall Response Rate (ORR) improvement to 86% at the end of Year 2, up from 72% at Year 1 [5][6] - The Complete Response (CR) rate increased from 28% in Year 1 to 50% in Year 2, indicating that half of the patients required no surgeries at all [5][6] - The mean number of surgeries needed dropped from 4.1 per year prior to treatment to 1.7 in Year 1 and further to 0.9 in Year 2 [5][6] Safety and Tolerability - INO-3107 was well tolerated, with no serious adverse events or long-term safety concerns reported [6][8] - Most treatment-emergent adverse effects were low-grade, such as injection site pain and fatigue [8] Market Potential and Regulatory Designations - INOVIO believes that the sustained reduction in surgeries could position INO-3107 as a preferred treatment option for RRP if approved [2][9] - The FDA has granted INO-3107 Orphan Drug and Breakthrough Therapy designations, allowing for accelerated approval processes [9] - INOVIO has also received CE-marking for its CELLECTRA delivery device in the EU, facilitating commercialization [9] Background on RRP and INO-3107 - RRP is a rare disease primarily caused by HPV-6 and HPV-11, leading to benign growths in the respiratory tract that can cause severe complications [4][8] - INO-3107 is designed to elicit a T cell response against HPV-6 and HPV-11, potentially preventing or slowing the growth of new papillomas [8][11]

Core Insights - INOVIO is on track to submit its Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis (RRP), in mid-2025, with the goal of FDA acceptance by the end of 2025 [2][3][7] - The company reported a decrease in net loss for Q1 2025 to $19.7 million, or $0.51 per share, compared to a net loss of $30.5 million, or $1.31 per share, in Q1 2024 [15][19] - INOVIO's cash, cash equivalents, and short-term investments were $68.4 million as of March 31, 2025, down from $94.1 million at the end of 2024, with an estimated operational net cash burn of approximately $22 million for Q2 2025 [12][15] Company Developments - INOVIO has initiated device design verification testing for the CELLECTRA device, which is required for the BLA submission, expected to be completed in the first half of 2025 [3][7] - The company is conducting ongoing market research to support its commercial readiness plans and has published clinical data from a Phase 1/2 trial in a peer-reviewed journal [4][6] - Promising interim results from a Phase 1 proof-of-concept trial for DNA-encoded monoclonal antibodies (DMAbs) were announced, with additional data to be presented at upcoming scientific meetings [6][9] Financial Performance - Research and development expenses decreased to $16.1 million in Q1 2025 from $20.9 million in Q1 2024, primarily due to lower drug manufacturing and immunology expenses [15] - General and administrative expenses also decreased to $9.0 million in Q1 2025 from $10.6 million in Q1 2024, attributed to lower legal expenses and stock-based compensation [15] - Total operating expenses for Q1 2025 were $25.1 million, down from $31.5 million in the same period of 2024 [15][19]

Core Insights - INOVIO is focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, and will present at several upcoming conferences to share new data on its lead candidate INO-3107 [1][4] Conference Presentations - INOVIO will participate in the Citizens JMP Life Sciences Conference on May 8, featuring a fireside chat format [2] - At the European Laryngological Society Annual Congress on May 9, INOVIO will present data showing that INO-3107 generates a targeted immunologic response, resulting in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in the first year [2] - The American Society of Gene and Cell Therapy will host a poster abstract session on May 13, discussing the successful treatment of recurrent respiratory papillomatosis with INO-3107, regardless of papilloma microenvironment and molecular subtype [2] - An oral presentation at the ABEA program during the COSM on May 15 will focus on the durability and long-term clinical effects of INO-3107 in treating recurrent respiratory papillomatosis caused by HPV types 6 and 11 [3] Company Overview - INOVIO is a biotechnology company that specializes in the design and delivery of innovative DNA medicines, aiming to empower the body to produce its own disease-fighting tools [4]